Reata announces positive phase 2 data for bardoxolone methyl in patients with FSGS
Reata announced positive, final results from the focal segmental glomerulosclerosis cohort of PHOENIX, a Phase 2 study of bardoxolone methyl (bardoxolone) in patients with rare forms of CKD. Compared to baseline, bardoxolone significantly improved kidney function the primary endpoint. February 20, 2019